Targets › HHLA2
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Aug 2027.
Through interaction with TMIGD2, costimulates T-cells in the context of TCR-mediated activation. Enhances T-cell proliferation and cytokine production via an AKT-dependent signaling cascade. (UniProt, Q9UM44)
Open in Phaseline: the race on HHLA2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| NextPoint Therapeutics | NPX887 B7-H7/HHLA2 antagonistic monoclonal antibody | HHLA2 | Phase 1 | Metastatic Malignant Neoplasm | Aug 2027 |
Metastatic Malignant Neoplasm (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.